AptuCure bio target the immune system to pathologic markers via fully synthetic AptuBodies.

​

AptuCure Bio is developing AptuBodies: unique revolutionary synthetic aptamer-based nanoparticles mimicking antibody activity, that can be directed virtually against any target. An AptuBody binds non-covalently to the Fab fragment of circulating IgG antibody and thus provides the antibody a new antigen binding domain, targeted to a designed cell surface markers. An AptuBody will complex with any IgG, directing the complex to its target and activating safe natural complement-mediated immune response. The AptuBodies/IgG complex mimics therapeutic antibodies, by binding to cell surface antigens and promote activation of the natural immune system which aimed to kill the target cells, such as the complement system and killer cells. AptuBodies can replace humanized antibodies, for the treatment of cancer, infectious disease, and auto-immune disease.

 

In-Vitro:

AptuBodies showed antibacterial activity against Listeria in culture, and specific anti-tumor activity in cell culture expressing MUC1 breast cancer biomarker.

 

In-Vivo:

Preliminary toxicity studies in mice showed no effect of the AptuBodies.

Studies in mice showed significantly improved pharmacokinetics, this is due to AptuBodies binds the circulating IgG that overcome aptamer’s unwanted fast secretion.

​

 

 

AptuCure bio LTD was Founded by Ofer Nussbaum PhD and Boaz Musafia PhD in 2018.

Awarded support from the Israeli innovation authority.

Concept patent was approved in USA (US20190352642A1) and Israel (IL267782) and pending in EU CH and CA.